帕妥珠单抗联合TP新辅助化疗方案对HER2阳性乳腺癌患者的影响分析  

Effect of Pertuzumab Combined with TP Neoadjuvant Chemotherapy on HER2-positive Breast Cancer Patients

作　　者：张桂玲 Zhang Guiling(Department of Pathology,Chengwu County People's Hospital,Heze City,Heze 274200,Shandong Province,China)

机构地区：[1]菏泽市成武县人民医院病理科,山东菏泽274200

出　　处：《中外医药研究》2024年第4期41-43,共3页JOURNAL OF CHINESE AND FOREIGN MEDICINE AND PHARMACY RESEARCH

摘　　要：目的:探讨帕妥珠单抗联合紫杉类和铂类药物(TP)新辅助化疗方案对人表皮生长因子受体2(HER2)阳性乳腺癌患者免疫功能的影响及安全性分析.方法:选取2021年1月—2023年1月成武县人民医院收治的HER2阳性乳腺癌患者80例为研究对象,随机分为对照组和观察组,各40例.对照组采用TP新辅助化疗方案治疗,观察组在对照组基础上联合帕妥珠单抗治疗.比较两组治疗效果.结果:观察组肿瘤控制率高于对照组,差异有统计学意义(P=0.045);治疗后,两组CD4^(+)、CD4^(+)/CD8^(+)水平高于治疗前,CD8^(+)水平低于治疗前,且观察组优于对照组,差异有统计学意义(P<0.05);治疗后,两组半胱氨酸天冬氨酸蛋白酶-3、生存素水平均降低,且观察组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05).结论:帕妥珠单抗联合TP新辅助化疗方案治疗HER2阳性乳腺癌有较好的肿瘤控制率,能改善机体免疫功能,调节乳腺组织凋亡分子平衡,且不会增加不良反应发生率.Objective:To investigate the effect and safety of pertuzumab combined with Yew and platinum drug(TP)neoadjuvant chemotherapy on immune function of human epidermal growth factor receptor 2(HER2)positive breast cancer patients.Methods:A total of 80 patients with HER2-positive breast cancer were selected as the study objects at Chengwu County People's Hospital from January 2021 to January 2023,and were randomly divided into control group and observation group,with 40 patients in each group.The control group was treated with TP neoadjuvant chemotherapy,and the observation group was treated with pertuzumab on the basis of control group.The therapeutic effect of the two groups was compared.Results:The tumor control rate in observation group was higher than that in control group,the difference was statistically significant(P=0.045);after treatment,the levels of CD4^(+)and CD4^(+)/CD8^(+)were higher than before treatment,and the level of CD8^(+)was lower than before treatment,and the observation group was better than the control group,the difference was statistically significant(P<0.05);after treatment,the levels of cysteine aspartic protease-3 and survivin in 2 groups were decreased,and the observation group was lower than the control group,the difference was statistically significant(P<0.05);there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Pertuzumab combined with TP neoadjuvant chemotherapy in the treatment of HER2-positive breast cancer has a good tumor control rate,can improve the immune function of the body,regulate the molecular balance of breast tissue apoptosis,and does not increase the incidence of adverse reactions.

关 键 词：人表皮生长因子受体2 乳腺癌 帕妥珠单抗 紫杉类和铂类药物新辅助化疗方案 肿瘤控制率 免疫功能 

分 类 号：R737.9[医药卫生—肿瘤]